IDH1 and glioma: Recently, Luo et al. proved that integrating the clonal status into classification could provide more precise stratification in diffuse gliomas and showed that gliomas with subclonal IDH mutation and without 1p/19q codeletion could be a novel subgroup and significantly correlated with patients' clinical outcomes [19].